{"id":622916,"date":"2024-06-26T09:38:54","date_gmt":"2024-06-26T13:38:54","guid":{"rendered":"https:\/\/platohealth.ai\/intellia-says-its-crispr-based-therapy-can-be-redosed\/"},"modified":"2024-06-26T10:29:26","modified_gmt":"2024-06-26T14:29:26","slug":"intellia-says-its-crispr-based-therapy-can-be-redosed","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/intellia-says-its-crispr-based-therapy-can-be-redosed\/","title":{"rendered":"Intellia says its CRISPR-based therapy can be redosed","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<p><em>Want to stay on top of the science and politics driving biotech today?&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>&nbsp;to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Good morning. It\u2019s Wednesday, which means it\u2019a also \u201cThe Bear\u201d season 3 premiere day. For my Boston readers, know that Ayo Edebiri <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/x.com\/LateNightSeth\/status\/1804685895221600707?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">has been thinking deeply<\/a>&nbsp;about the tragedy of&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/en.wikipedia.org\/wiki\/Great_Molasses_Flood?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">the Great Molasses Flood of 1919<\/a>.<\/p>\n<div class=\"ad-in-article dfp-ad-midbreaker-wrap\">\n<p class=\"ad-label\">advertisement<\/p>\n<\/div>\n<p>Onto the biotech news of the day.<\/p>\n<h2>The need-to-know this morning<\/h2>\n<ul>\n<li>Lyell Immunopharma, the struggling Rick Klausner-founded CAR-T company,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/ir.lyell.com\/news-releases\/news-release-details\/lyell-immunopharma-reports-dose-dependent-clinical-activity?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-stringify-link=\"https:\/\/ir.lyell.com\/news-releases\/news-release-details\/lyell-immunopharma-reports-dose-dependent-clinical-activity\" data-sk=\"tooltip_parent\" data-hs-link-id=\"0\">reported<\/a>&nbsp;two responses but also a patient death in a breast cancer trial.<\/li>\n<li data-stringify-indent=\"0\" data-stringify-border=\"0\">Zealand Pharma is raising&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/25\/2904185\/0\/en\/Zealand-Pharma-announces-completion-of-an-upsized-equity-offering-of-8-35-million-new-ordinary-shares-raising-gross-proceeds-of-USD-1-billion-DKK-7-billion.html?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-stringify-link=\"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/25\/2904185\/0\/en\/Zealand-Pharma-announces-completion-of-an-upsized-equity-offering-of-8-35-million-new-ordinary-shares-raising-gross-proceeds-of-USD-1-billion-DKK-7-billion.html\" data-sk=\"tooltip_parent\" data-hs-link-id=\"0\">nearly<\/a>&nbsp;$1 billion to fund its obesity efforts.<\/li>\n<\/ul>\n<h2>\u2018Free the founders\u2019 accelerator raises new fund<\/h2>\n<p>The biotech startup accelerator Curie.Bio has raised $380 million for a new fund, the organization exclusively told STAT. The money will be invested in biotechs that go through the accelerator and go on to raise a Series A round, though Curie.Bio may occasionally also invest in companies outside the accelerator.<\/p>\n<p>Launched last year by&nbsp;industry veterans Alexis Borisy and Zach Weinberg, Curie.Bio aims to offer an alternative to the traditional ways drug startups are financed, which can leave founders with little say or financial stake in their companies. The accelerator adopted the mantra \u201cfree the founders,\u201d which has been plastered on billboards and buses in biotech hubs nationwide.<\/p>\n<div class=\"ad-in-article dfp-ad-midbreaker2-wrap\">\n<p class=\"ad-label\">advertisement<\/p>\n<\/div>\n<p><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/06\/26\/curie-bio-accelerator-new-fund\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\">Read more<\/a>&nbsp;from STAT\u2019s Allison DeAngelis.<\/p>\n<h2>Intellia says its CRISPR-based therapy can be redosed<\/h2>\n<p>Intellia&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-announces-positive-clinical-proof-concept-data-redosing?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">reported<\/a>&nbsp;early data yesterday showing that its CRISPR-based therapy that targets a harmful protein called TTR can be redosed. This is the first-ever clinical data showing redosing with an in vivo CRISPR-based therapy, the company said.<\/p>\n<p>The data are from an ongoing Phase 1 study of the therapy, NTLA-2001. Three patients who received redosing experienced a 90% median reduction in serum TTR at 28 days, and it was well-tolerated, Intellia said.<\/p>\n<p>The therapy is currently also in Phase 3 trials for the heart condition ATTR-CM and a rare nerve condition called ATTRv-PN. While redosing is not planned for these studies, the new data show the potential to redose in other disease areas where more than one dose may be needed to reach the desired benefit, the company said.<\/p>\n<p>Investors are closely watching Intellia\u2019s program in ATTR-CM after Alnylam&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/06\/24\/alnylam-vutrisiran-results-helios-b-attr-cm\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\">reported<\/a>&nbsp;positive data on its RNAi treatment earlier this week. Stifel analyst Dae Gon Ha wrote that Alnylam\u2019s results bode well for Intellia, due to similarities in the approaches that aim to stop production of the TTR protein. \u201cThe HELIOS-B outcome has done the heavy lifting \u2013 by validating RNAi against hard endpoints in ATTR-CM, a CRISPR-based gene knockout should have little reason for a dramatically divergent outcome,\u201d Ha said.<\/p>\n<h2>How a Flagship startup is using AI to study cell biology<\/h2>\n<p>Cellarity, a startup launched by Flagship Pioneering, is trying to use AI to understand the full biology of cells and find new ways to treat disease. The company views traditional drug discovery as \u201creductionist,\u201d since it reduces diseases to one or two targets rather than embracing the complexity of cell biology.<\/p>\n<p>With the startup in the middle of raising a Series D, the last round it hopes to raise before going public, STAT\u2019s Brittany Trang sat down with its CEO and one of its head scientists to discuss the company\u2019s approach.<\/p>\n<p><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/06\/26\/cellarity-flagship-using-ai-drug-discovery?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\">Read more<\/a>.<\/p>\n<h2>Wegovy will soon be available in a major new market<\/h2>\n<p>China has approved Novo Nordisk\u2019s obesity drug Wegovy, opening the drug up to a massive new market. Recent survey data suggest that more than half of Chinese adults are overweight or have obesity, according to&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.thelancet.com\/series\/obesity-in-china?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">a Lancet series<\/a>.<\/p>\n<p>Novo shares were up yesterday on the news, but&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novo-nordisk-says-semaglutide-approved-long-term-weight-management-china-2024-06-25\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">as Reuters points out<\/a>, the company may not maintain a lead on the obesity market in China for long. Novo\u2019s patent on semaglutide, the active ingredient in Wegovy and in the sister diabetes drug Ozempic, is set to expire in less than two years in China, while it has a patent until 2031 in Europe and Japan and until 2032 in the U.S.<\/p>\n<p>It\u2019s also not clear how Novo would handle supplying drugs for such a populous country. Novo (as well as its rival Lilly) have run into recurrent shortages with their GLP-1-based drugs due to the immense demand, even as the companies rapidly ramp up manufacturing capacity.<\/p>\n<h2>Home sweet home<\/h2>\n<p>If you\u2019ve ever wanted to live in the offices of one of the world\u2019s largest pharmaceutical companies \u2014 now is your chance.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/platohealth.ai\/wp-content\/uploads\/2024\/06\/intellia-says-its-crispr-based-therapy-can-be-redosed.jpg\"><\/p>\n<h5 align=\"right\">KENA BETANCUR\/AFP via Getty Images<\/h5>\n<p>It turns out Pfizer\u2019s former New York headquarters on 42nd St are being converted into 1,500 apartments in the biggest conversion in the city\u2019s history,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/x.com\/MarkLevineNYC\/status\/1805692077231022127?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">according to the Manhattan Borough president<\/a>.<\/p>\n<h2>More reads<\/h2>\n<ul>\n<li>Eli Lilly inks OpenAI deal for discovering new antibiotics,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.fiercebiotech.com\/biotech\/eli-lilly-inks-openai-deal-discovering-new-antibiotics?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">Fierce Biotech<\/a><\/li>\n<li>AbbVie Parkinson\u2019s Drug Rejected by FDA After Plant Inspection,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.bloomberg.com\/news\/articles\/2024-06-25\/abbvie-parkinson-s-drug-rejected-by-fda-after-plant-inspection?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">Bloomberg<\/a><\/li>\n<li>Arrowhead shelves one cardiometabolic drug candidate, focuses on another,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/endpts.com\/arrowhead-shelves-one-cardiometabolic-drug-candidate-focuses-on-another\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\" data-hs-link-id=\"0\">Endpoints<\/a><\/li>\n<li>Stop allowing MA plans to use AI to deny care without review, lawmakers urge CMS,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/06\/25\/medicare-advantage-ai-tools-denial-unitedhealth-lawmawkers-cms\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_HZalGz6ujJ5XFyfuLsz8paorziYxEckVSIalQ5TDMCN84dD-NkQFEPsdd5pgCG7kPn2t8\">STAT<\/a><\/li>\n<\/ul>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.amplifipr.com\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platodata-network\">PlatoData.Network Vertical Generative Ai. Empower Yourself. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platodata.network\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoaistream\">PlatoAiStream. Web3 Intelligence. Knowledge Amplified. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoesg\">PlatoESG. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/carbon\/\">Carbon,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/cleantech\/\">CleanTech,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/energy\/\">Energy,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/environment\/\">Environment,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/solar\/\">Solar,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/waste-management\/\">Waste Management.<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platohealth\">PlatoHealth. Biotech and Clinical Trials Intelligence. <a href=\"https:\/\/platohealth.ai\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/06\/26\/biotech-news-lyell-intellia-cellarity-zealand-eli-lilly-abbvie-crispr-ai-cell-biology\/?utm_campaign=rss\">https:\/\/www.statnews.com\/2024\/06\/26\/biotech-news-lyell-intellia-cellarity-zealand-eli-lilly-abbvie-crispr-ai-cell-biology\/?utm_campaign=rss<\/a><\/li>\n<\/ul>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Want to stay on top of the science and politics driving biotech today?&nbsp;Sign up&nbsp;to get our biotech newsletter in your inbox. Good morning. It\u2019s Wednesday, which means it\u2019a also \u201cThe Bear\u201d season 3 premiere day. For my Boston readers, know that Ayo Edebiri has been thinking deeply&nbsp;about the tragedy of&nbsp;the Great Molasses Flood of 1919. [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":622919,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622916"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=622916"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622916\/revisions"}],"predecessor-version":[{"id":622918,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622916\/revisions\/622918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/622919"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=622916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=622916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=622916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}